Supernus Pharmaceuticals (SUPN) Income from Continuing Operations (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Income from Continuing Operations of 58371000.0 for Q2 2026, down 359.44% year-over-year from 22499000.0 in Q2 2025, and down 1311.97% on a QoQ basis from 4134000.0 in Q4 2025.
Supernus Pharmaceuticals (SUPN) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Income from Continuing Operations for 16 years, with the latest figure at 58371000.0 in Q2 2026.
- Income from Continuing Operations for Q2 2026 came in at 58371000.0, down 359.44% year-over-year; the trailing twelve-month figure through Jun 2026 was 85123000.0 (down 231.89% YoY), and the FY2025 annual result was 38550000.0, down 152.19% from the prior year.
- Income from Continuing Operations fell to 58371000.0 in Q2 2026, from 4134000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 38497000.0 in Q3 2024 and troughed at 58371000.0 in Q2 2026.
- A 5-year average of 2289117.65 and a median of 1756000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest annual swing landed in 2024, when Income from Continuing Operations jumped 2506.53%; it then slumped 9641.13% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 25481000.0 in 2022, then tumbled by 95.39% to 1175000.0 in 2023, then jumped by 1208.68% to 15377000.0 in 2024, then slumped by 126.88% to 4134000.0 in 2025, then sank by 1311.97% to 58371000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 58371000.0 in Q2 2026, 4134000.0 in Q4 2025, and 45117000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | -58.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -58.37 Mn |
| Dec 31, 2025 | -4.11 Mn |
| Sep 30, 2025 | -45.12 Mn |
| Jun 30, 2025 | 22.50 Mn |
| Mar 31, 2025 | -11.83 Mn |
| Dec 31, 2024 | 15.33 Mn |
| Sep 30, 2024 | 38.54 Mn |
| Jun 30, 2024 | 19.90 Mn |
| Mar 31, 2024 | 143,000.00 |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | -15.98 Mn |
| Jun 30, 2023 | -827,000.00 |
| Mar 31, 2023 | 16.95 Mn |
| Dec 31, 2022 | 25.51 Mn |
| Sep 30, 2022 | 1.75 Mn |
| Jun 30, 2022 | 7.87 Mn |
| Mar 31, 2022 | 25.62 Mn |
| Dec 31, 2021 | 2.44 Mn |
| Sep 30, 2021 | 21.56 Mn |
| Jun 30, 2021 | 23.73 Mn |